p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines

Head and Neck

Volumn 25, Issue 8, 2003, Pages 654-661

  Bradford, Carol R ^a   Zhu, Shaobo ^a,c   Ogawa, Haruko ^a,d   Ogawa, Tetsuya ^a   Ubell, Matthew ^a   Narayan, Ajita ^a   Johnson, Garfield ^a   Wolf, Gregory T ^a   Fisher, Susan G ^b,e   Carey, Thomas E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GIFU UNIVERSITY   (Japan)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Head and neck; Neoplasms; p53; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GENOMIC DNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; DNA SEQUENCE; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EXONS; GENE EXPRESSION; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0041342137     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10274     Document Type: Article

References (30)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
2. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491-7495.
3. Milner J. Flexibility: the key to p53 function? Trends Biochem Sci 1995;20:49-51.
4. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993;82:1092-1096.
5. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
6. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995; 113:408-412.
7. Bradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999;121:534-538.
8. Fan S, el-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54:5824-5830.
9. Fan S, Smith ML, Rivet DJ 2nd, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-1654.
10. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
11. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992;52:5323-5328.
12. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-1216.
13. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86:1903-1910.
14. Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002;112:638-644.
15. Akervall J, Kurnit DM, Adams M, Zhu S, Fisher SG, Bradford CR, Carey TE. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Submitted, Laryngoscope, 2002.
16. Bradford CR, Zhu S, Poore J, et al. T. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg 1997;123:605-609.
17. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18:477-485.
18. Asada N, Tsuchiya H, Tomita K. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res 1999;19:5131-5137.
19. Fan J, Bertino JR. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol Pharmacol 1999;56:966-972.
20. Bartussek C, Naumann U, Welle, M. Accumulation of mutant p53 (V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Exp Cell Res 1999;253:432-439.
21. Chang FL, Lai MD. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J Urol 2001;166:304-310.
22. Cabelguenne A, Blons H, de Waziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465-1473.
23. Obata A, Eura M, Sasaki J, et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 2000;89:187-193.
24. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-1586.
25. Grenman R, Carey TE, McClatchey KD, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 1991;67:2741-2747.
26. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999;18:7690-7700.
27. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001;93:232-235.
28. Gu J, Rubin RM, Yuan ZM. A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. Oncogene 2001;20:3519-3527.
29. Mantovani F, Banks L. The interaction between p53 and papillomaviruses. Semin Cancer Biol 1999;9:387-395.
30. Ahrendt S, Halachmi S, Chow JT, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA 1999; 96:9382-9387.